Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012, Article ID 973820, 9 pages
http://dx.doi.org/10.1155/2012/973820
Review Article

Prostate-Specific Membrane Antigen-Based Therapeutics

1Division of Hematology and Medical Oncology, Weill Cornell Medical College, 525 E. 68th Street, Box 403, New York, NY 10065, USA
2Department of Urology, Weill Cornell Medical College, 525 E. 68th Street, Box 403, New York, NY 10065, USA

Received 2 May 2011; Accepted 9 May 2011

Academic Editor: Maximilian Burger

Copyright © 2012 Naveed H. Akhtar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Horoszewicz, E. Kawinski, and G. P. Murphy, “Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients,” Anticancer Research, vol. 7, no. 5, pp. 927–935, 1987. View at Google Scholar · View at Scopus
  2. R. S. Israeli, C. T. Powell, W. R. Fair, and W. D. W. Heston, “Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen,” Cancer Research, vol. 53, no. 2, pp. 227–230, 1993. View at Google Scholar · View at Scopus
  3. R. S. Israeli, C. T. Powell, J. G. Corr, W. R. Fair, and W. D. W. Heston, “Expression of the prostate-specific membrane antigen,” Cancer Research, vol. 54, no. 7, pp. 1807–1811, 1994. View at Google Scholar · View at Scopus
  4. G. L. Wright, C. Haley, M. L. Beckett, and P. F. Schellhammer, “Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues,” Urologic Oncology, vol. 1, no. 1, pp. 18–28, 1995. View at Publisher · View at Google Scholar
  5. J. K. Troyer, M. L. Beckett, and G. L. Wright Jr., “Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids,” International Journal of Cancer, vol. 62, no. 5, pp. 552–558, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Sokoloff, K. C. Norton, C. L. Gasior, K. M. Marker, and L. S. Grauer, “A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine,” Prostate, vol. 43, no. 2, pp. 150–157, 2000. View at Google Scholar · View at Scopus
  7. D. G. Bostwick, A. Pacelli, M. Blute, P. Roche, and G. P. Murphy, “Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases,” Cancer, vol. 82, no. 11, pp. 2256–2261, 1998. View at Google Scholar · View at Scopus
  8. T. Kusumi, T. Koie, M. Tanaka et al., “Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy,” Pathology International, vol. 58, no. 11, pp. 687–694, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. Mannweiler, P. Amersdorfer, S. Trajanoski, J. A. Terrett, D. King, and G. Mehes, “Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis,” Pathology and Oncology Research, vol. 15, no. 2, pp. 167–172, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. H. J. K. Ananias, M. C. van den Heuvel, W. Helfrich, and I. J. De Jong, “Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer,” Prostate, vol. 69, no. 10, pp. 1101–1108, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. G. L. Wright Jr., B. M. Grob, C. Haley et al., “Upregulation of prostate-specific membrane antigen after androgen- deprivation therapy,” Urology, vol. 48, no. 2, pp. 326–334, 1996. View at Publisher · View at Google Scholar
  12. S. D. Sweat, A. Pacelli, G. P. Murphy, and D. G. Bostwick, “Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases,” Urology, vol. 52, no. 4, pp. 637–640, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. S. S. Chang, V. E. Reuter, W. D. W. Heston, N. H. Bander, L. S. Grauer, and P. B. Gaudin, “Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature,” Cancer Research, vol. 59, no. 13, pp. 3192–3198, 1999. View at Google Scholar · View at Scopus
  14. J. T. Pinto, B. P. Suffoletto, T. M. Berzin et al., “Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells,” Clinical Cancer Research, vol. 2, no. 9, pp. 1445–1451, 1996. View at Google Scholar
  15. D. Kahn, R. D. Williams, M. K. Haseman, N. L. Reed, S. J. Miller, and J. Gerstbrein, “Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 284–289, 1998. View at Google Scholar
  16. D. Kahn, R. D. Williams, M. J. Manyak et al., “111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy,” Journal of Urology, vol. 159, no. 6, pp. 2041–2047, 1998. View at Google Scholar
  17. M. J. Manyak, “Indium-111 capromab pendetide in the management of recurrent prostate cancer,” Expert Review of Anticancer Therapy, vol. 8, no. 2, pp. 175–181, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. K. Bouchelouche, S. T. Tagawa, S. J. Goldsmith, B. Turkbey, J. Capala, and P. Choyke, “PET/CT imaging and radioimmunotherapy of prostate cancer,” Seminars in Nuclear Medicine, vol. 41, no. 1, pp. 29–44, 2011. View at Publisher · View at Google Scholar · View at PubMed
  19. J. K. Troyer, M. L. Beckett, and G. L. Wright Jr., “Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line,” Prostate, vol. 30, no. 4, pp. 232–242, 1997. View at Google Scholar · View at Scopus
  20. H. Liu, P. Moy, S. Kim et al., “Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium,” Cancer Research, vol. 57, no. 17, pp. 3629–3634, 1997. View at Google Scholar
  21. H. Liu, A. K. Rajasekaran, P. Moy et al., “Constitutive and antibody-induced internalization of prostate-specific membrane antigen,” Cancer Research, vol. 58, no. 18, pp. 4055–4060, 1998. View at Google Scholar · View at Scopus
  22. D. Yao, E. J. Trabulsi, L. Kostakoglu et al., “The utility of monoclonal antibodies in the imaging of prostate cancer,” Seminars in Urologic Oncology, vol. 20, no. 3, pp. 211–218, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. N. H. Bander, D. M. Nanus, M. I. Milowsky, L. Kostakoglu, S. Vallabahajosula, and S. J. Goldsmith, “Targeted systemic therapy of prostate cancer With a monoclonal antibody to prostate-specific membrane antigen,” Seminars in Oncology, vol. 30, no. 5, pp. 667–677, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Divgi, “What ails solid tumor radioimmunotherapy?” Cancer Biotherapy and Radiopharmaceuticals, vol. 21, no. 2, pp. 81–84, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. A. O'Donoghue, M. Bardies, T. E. Wheldon, and G. Sgouros, “Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides,” Journal of Nuclear Medicine, vol. 36, no. 10, pp. 1902–1912, 1995. View at Google Scholar · View at Scopus
  26. N. Deb, M. Goris, K. Trisler et al., “Treatment of hormone-refractory prostate cancer with Y-CYT-356 monoclonal antibody,” Clinical Cancer Research, vol. 2, no. 8, pp. 1289–1297, 1996. View at Google Scholar · View at Scopus
  27. D. Kahn, J. C. Austin, R. T. Maguire, S. J. Miller, J. Gerstbrein, and R. D. Williams, “A phase II study of [90Y]yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy,” Cancer Biotherapy and Radiopharmaceuticals, vol. 14, no. 2, pp. 99–111, 1999. View at Google Scholar · View at Scopus
  28. R. F. Meredith, A. J. Bueschen, M. B. Khazaeli et al., “Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49,” Journal of Nuclear Medicine, vol. 35, no. 6, pp. 1017–1022, 1994. View at Google Scholar · View at Scopus
  29. R. T. O'Donnell, S. J. DeNardo, A. Yuan et al., “Radioimmunotherapy with In/Y-2IT-BAD-m170 for metastatic prostate cancer,” Clinical Cancer Research, vol. 7, no. 6, pp. 1561–1568, 2001. View at Google Scholar · View at Scopus
  30. R. T. O'Donnell, S. J. Denardo, L. A. Miers et al., “Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and Yttrium-DOTA-peptide-ChL6,” Prostate, vol. 50, no. 1, pp. 27–37, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. C. M. Richman, S. J. DeNardo, R. T. O'Donnell et al., “High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody,” Clinical Cancer Research, vol. 11, no. 16, pp. 5920–5927, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. P. Kelly, F. T. Lee, K. Tahtis, F. E. Smyth, M. W. Brechbiel, and A. M. Scott, “Radioimmunotherapy with α-particle—emitting 213Bi-C- functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy,” Clinical Cancer Research, vol. 13, no. 18, pp. 5604s–5612s, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. D. W. Schneider, T. Heitner, B. Alieke et al., “In vivo bodistribution, PET imaging, and tumor accumulation of 86Y-and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice,” Journal of Nuclear Medicine, vol. 50, no. 3, pp. 435–443, 2009. View at Publisher · View at Google Scholar · View at PubMed
  34. M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, S. J. Goldsmith, and N. H. Bander, “Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer,” Journal of Clinical Oncology, vol. 22, no. 13, pp. 2522–2531, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. N. H. Bander, M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, and S. J. Goldsmith, “Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4591–4601, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. T. Tagawa, H. Beltran, S. Vallabhajosula et al., “Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer,” Cancer, vol. 116, no. 4, supplement, pp. 1075–1083, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. G. L. DeNardo, J. Schlom, D. J. Buchsbaum et al., “Rationales, evidence, and design considerations for fractionated radioimmunotherapy,” Cancer, vol. 94, no. 4, supplement, pp. 1332–1348, 2002. View at Google Scholar · View at Scopus
  38. J. A. O'Donoghue, G. Sgouros, C. R. Divgi, and J. L. Humm, “Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry,” Journal of Nuclear Medicine, vol. 41, no. 3, pp. 538–547, 2000. View at Google Scholar · View at Scopus
  39. S. Shen, J. Duan, R. F. Meredith et al., “Model prediction of treatment planning for dose-fractionated radioimmunotherapy,” Cancer, vol. 94, no. 4, supplement, pp. 1264–1269, 2002. View at Google Scholar · View at Scopus
  40. L. A. Kroger, G. L. DeNardo, P. H. Gumerlock et al., “Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy,” Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 3, pp. 213–225, 2001. View at Google Scholar
  41. H. M. Vriesendorp, Y. Shao, J. E. Blum, S. M. Quadri, and J. R. Williams, “Fractionated intravenous administration of Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs,” Nuclear Medicine and Biology, vol. 20, no. 5, pp. 571–578, 1993. View at Google Scholar · View at Scopus
  42. D. Buchsbaum, M. B. Khazaeli, T. Liu et al., “Fractionated radioimmumotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49,” Cancer Research, vol. 55, no. 23, supplement, pp. 5881S–5887S, 1995. View at Google Scholar
  43. G. L. DeNardo, S. J. DeNardo, K. R. Lamborn et al., “Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody,” Cancer Biotherapy and Radiopharmaceuticals, vol. 13, no. 4, pp. 239–254, 1998. View at Google Scholar · View at Scopus
  44. M. G. Steffens, O. C. Boerman, W. J. G. Oyen et al., “Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy,” Cancer Research, vol. 59, no. 7, pp. 1615–1619, 1999. View at Google Scholar · View at Scopus
  45. C. Hindorf, O. Lindén, L. Stenberg, J. Tennvall, and S. E. Strand, “Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients,” Clinical Cancer Research, vol. 9, no. 10, pp. 4003S–4006S, 2003. View at Google Scholar · View at Scopus
  46. M. P. Kelly, F. T. Lee, F. E. Smyth, M. W. Brechbiel, and A. M. Scott, “Enhanced efficacy of Y-radiolabeled anti-lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model,” Journal of Nuclear Medicine, vol. 47, no. 4, pp. 716–725, 2006. View at Google Scholar · View at Scopus
  47. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., “American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. P. Holland, V. Divilov, N. H. Bander, P. M. Smith-Jones, S. Larson, and J. S. Lewis, “89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo,” Journal of Nuclear Medicine, vol. 51, no. 8, pp. 1293–1300, 2010. View at Publisher · View at Google Scholar · View at PubMed
  49. S. N. Khleif, J. H. Doroshow, and W. N. Hait, “AACR-FDA-NCI cancer biomarkers collaborative consensus report: advancing the use of biomarkers in cancer drug development,” Clinical Cancer Research, vol. 16, no. 13, pp. 3299–3318, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. S. T. Tagawa, M. I. Milowsky, M. Morris et al., “Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC),” Journal of Clinical Oncology, vol. 26, no. 15, supplement, p. 284s, 2008, abstract no. 5140. View at Google Scholar
  51. S.T. Tagawa, S. Vallabhajosula, J. Osborne et al., “Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, abstract no. 4667. View at Google Scholar
  52. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. H. Choy, F. F. Rodriguez, S. Koester, S. Hilsenbeck, and D. D. Von Hoff, “Investigation of taxol as a potential radiation sensitizer,” Cancer, vol. 71, no. 11, pp. 3774–3778, 1993. View at Google Scholar · View at Scopus
  55. R. B. Tishler, P. B. Schiff, C. R. Geard, and E. J. Hall, “Taxol: a novel radiation sensitizer,” International Journal of Radiation Oncology Biology Physics, vol. 22, no. 3, pp. 613–617, 1992. View at Google Scholar · View at Scopus
  56. C. Hennequin, N. Giocanti, and V. Favaudon, “Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in HeLa and SQ20B cells,” Cancer Research, vol. 56, no. 8, pp. 1842–1850, 1996. View at Google Scholar · View at Scopus
  57. H. Beltran, S. Vallabhajosula, W. K. Kelly et al., “Phase I dose escalation study of Docetaxel/Predisone and fractionated 177Lu -J591 for metastatic castrate resistant prostate cancer (metCRPC),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, abstract no. TPS247. View at Google Scholar
  58. M. S. Kaminski, J. Estes, K. R. Zasadny et al., “Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience,” Blood, vol. 96, no. 4, pp. 1259–1266, 2000. View at Google Scholar · View at Scopus
  59. M. S. Kaminski, A. D. Zelenetz, O. W. Press et al., “Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas,” Journal of Clinical Oncology, vol. 19, no. 19, pp. 3918–3928, 2001. View at Google Scholar · View at Scopus
  60. O. W. Press, J. M. Unger, R. M. Braziel et al., “A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: southwest Oncology Group Protocol S9911,” Blood, vol. 102, no. 5, pp. 1606–1612, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. M. S. Kaminski, M. Tuck, J. Estes et al., “I-tositumomab therapy as initial treatment for follicular lymphoma,” The New England Journal of Medicine, vol. 352, no. 5, pp. 441–449, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. J. P. Leonard, M. Coleman, L. Kostakoglu et al., “Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5696–5704, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. O. W. Press, J. M. Unger, R. M. Braziel et al., “Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4143–4149, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. J. W. Moul, “Prostate specific antigen only progression of prostate cancer,” Journal of Urology, vol. 163, no. 6, pp. 1632–1642, 2000. View at Google Scholar · View at Scopus
  65. H. I. Scher, M. Eisenberger, A. V. D'Amico et al., “Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group,” Journal of Clinical Oncology, vol. 22, no. 3, pp. 537–556, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. J. F. Pazona, M. Han, S. A. Hawkins, K. A. Roehl, and W. J. Catalona, “Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-Year outcome estimates,” Journal of Urology, vol. 174, no. 4, pp. 1282–1286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. S. J. Buskirk, T. M. Pisansky, S. E. Schild et al., “Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system,” Journal of Urology, vol. 176, no. 3, pp. 985–990, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. J. Stephenson, S. F. Shariat, M. J. Zelefsky et al., “Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy,” Journal of the American Medical Association, vol. 291, no. 11, pp. 1325–1332, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. J. F. Ward, H. Zincke, E. J. Bergstralh, J. M. Slezak, and M. L. Blute, “Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy,” Journal of Urology, vol. 172, no. 6, pp. 2244–2248, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. S. T. Tagawa, J. Osborne, P. J. Christos et al., “A randomized phase II trial of 177lu radiolabeled monoclonal antibody J591 (177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer after local therapy,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, abstract no. TPS248. View at Google Scholar
  71. S. C. Alley, N. M. Okeley, and P. D. Senter, “Antibody-drug conjugates: targeted drug delivery for cancer,” Current Opinion in Chemical Biology, vol. 14, no. 4, pp. 529–537, 2010. View at Publisher · View at Google Scholar · View at PubMed
  72. M. D. Henry, S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland, “A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer,” Cancer Research, vol. 64, no. 21, pp. 7995–8001, 2004. View at Publisher · View at Google Scholar · View at PubMed
  73. M. Galsky, M. Eisenberger, S. Moore-Cooper et al., “First in man study of the prostate specific membrane antigen targeted immunoconjugate, MLN2704, in patients with progressive castrate metastatic prostate cancer (PCMPC): updated results,” in Proceedings of the Prostate Cancer Symposium, Orlando, Fla, USA, 2005.
  74. X. Huang, M. Bennett, and P. E. Thorpe, “Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen,” Prostate, vol. 61, no. 1, pp. 1–11, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. P. J. Russell, D. Hewish, T. Carter et al., “Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: In vitro and in vivo studies,” Cancer Immunology, Immunotherapy, vol. 53, no. 5, pp. 411–421, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. M. D. Henry, S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland, “A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer,” Cancer Research, vol. 64, no. 21, pp. 7995–8001, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. U. Elsässer-Beile, P. Bühler, and P. Wolf, “Targeted therapies for Prostate cancer against the prostate specific membrane antigen,” Current Drug Targets, vol. 10, no. 2, pp. 118–125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Ma, C. E. Hopf, A. D. Malewicz et al., “Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen,” Clinical Cancer Research, vol. 12, no. 8, pp. 2591–2596, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. D. P. Petrylak, P. W. Kantoff, Y. Rotshteyn et al., “Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in taxane-refractory prostate cancer,” Journal of Clinical Oncology, vol. 29, supplement 7, 2011, abstract no. 158. View at Google Scholar
  80. S. R. Denmeade, “Prostate-specific membrane antigen activated prodrug and imaging agents,” abstract no. P19-58.
  81. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Publisher · View at Google Scholar · View at PubMed
  82. C. G. Drake, “Prostate cancer as a model for tumour immunotherapy,” Nature Reviews Immunology, vol. 10, no. 8, pp. 580–593, 2010. View at Publisher · View at Google Scholar · View at PubMed
  83. S. Alam and D. G. McNeel, “DNA vaccines for the treatment of prostate cancer,” Expert Review of Vaccines, vol. 9, no. 7, pp. 731–745, 2010. View at Publisher · View at Google Scholar · View at PubMed
  84. S. F. Slovin, “Prostate-specific membrane antigen vaccines: naked DNA and protein approaches,” Clinical Prostate Cancer, vol. 4, no. 2, pp. 118–123, 2005. View at Google Scholar · View at Scopus
  85. R. J. Durso, S. Andjelic, J. P. Gardner et al., “A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses,” Clinical Cancer Research, vol. 13, no. 13, pp. 3999–4008, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. M. Fishman, “A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer,” Expert Opinion on Biological Therapy, vol. 9, no. 12, pp. 1565–1575, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. Y. Kuang, H. Zhu, X. Weng et al., “Antitumor immune response induced by DNA vaccine encoding human prostate-specific membrane antigen and mouse 4-1BBL,” Urology, vol. 76, no. 2, pp. 510.e1–510.e6, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. B. Ferraro, N. J. Cisper, K. T. Talbott et al., “Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses,” Human Vaccines, vol. 7, pp. 120–127, 2011. View at Google Scholar
  89. N. H. Bander, D. Nanus, S. Bremer et al., “Phase I clinical trial targeting a monoclonal antibody (mAb) to the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer,” American Society of Clinical Oncology, vol. 19, 2000, abstract no. 1872. View at Google Scholar
  90. N. H. Bander, D. Nanus, S. Goldstein et al., “Phase I trial of humanized monoclonal antibody (mAb) to prostate specific membrane Antigen/Extracellular domain (PSMAext),” American Society of Clinical Oncology, vol. 20, 2001, abstract no. 722. View at Google Scholar
  91. M. J. Morris, C. R. Divgi, N. Pandit-Taskar et al., “Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer,” Clinical Cancer Research, vol. 11, no. 20, pp. 7454–7461, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. K. A. Smith, “Interleukin-2: inception, impact, and implications,” Science, vol. 240, no. 4856, pp. 1169–1176, 1988. View at Google Scholar · View at Scopus
  93. G. G. Hillman, J. A. Triest, M. L. Cher, S. V. Kocheril, and B. R. Talati, “Prospects of immunotherapy for the treatment of prostate carcinoma—a review,” Cancer Detection and Prevention, vol. 23, no. 4, pp. 333–342, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. K. A. Smith, “Lowest dose interleukin-2 immunotherapy,” Blood, vol. 81, no. 6, pp. 1414–1423, 1993. View at Google Scholar · View at Scopus
  95. T. A. Fehniger, E. M. Bluman, M. M. Porter et al., “Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy,” Journal of Clinical Investigation, vol. 106, no. 1, pp. 117–124, 2000. View at Google Scholar · View at Scopus
  96. S. J. Jeske, M. I. Milowsky, C. R. Smith, K. A. Smith, N. H. Bander, and D. M. Nanus , “Phase II trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus low-dose interleukin-2 (IL-2) in patients (pts) with recurrent prostate cancer (PC),” Journal of Clinical Oncology, vol. 25, no. 18, supplement, 2007, ASCO Annual Meeting Proceedings Part I, abstract no. 15558. View at Google Scholar